AAAAAA

   
Results: 1-15 |
Results: 15
Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity
Authors: Castilleja, A Ward, NE O'Brian, CA Swearingen, B Swan, E Gillogly, MA Murray, JL Kudelka, AP Gershenson, DM Ioannides, CG
Citation: A. Castilleja et al., Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity, MOL C BIOCH, 217(1-2), 2001, pp. 21-33
Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: Relationship to TAP expression
Authors: Murray, JL Hudson, JM Ross, MI Zhang, HZ Ioannides, CG
Citation: Jl. Murray et al., Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: Relationship to TAP expression, J IMMUNOTH, 23(1), 2000, pp. 28-35
Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides
Authors: Lee, TV Kim, DK Peoples, GE Castilleja, A Murray, JL Gershenson, DM Ioannides, CG
Citation: Tv. Lee et al., Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides, J INTERF CY, 20(4), 2000, pp. 391-401
Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals
Authors: Anderson, BW Peoples, GE Murray, JL Gillogly, MA Gershenson, DM Ioannides, CG
Citation: Bw. Anderson et al., Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals, CLIN CANC R, 6(11), 2000, pp. 4192-4200
Identification of activated tumor antigen-reactive CD8(+) cells in healthyindividuals
Authors: Lee, TV Anderson, BW Peoples, GE Castilleja, A Murray, JL Gershenson, DM Ioannides, CG
Citation: Tv. Lee et al., Identification of activated tumor antigen-reactive CD8(+) cells in healthyindividuals, ONCOL REP, 7(3), 2000, pp. 455-466
Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)
Authors: Yen, N Ioannides, CG Xu, K Swisher, SG Lawrence, DD Kemp, BL El-Naggar, AK Cristiano, RJ Fang, BL Glisson, BS Hong, WK Khuri, FR Kurie, JM Lee, JJ Lee, JS Merritt, JA Mukhopadhyay, T Nesbitt, JC Nguyen, D Perez-Soler, R Pisters, KMW Putnam, JB Schrump, DS Shin, DM Walsh, GL Roth, JA
Citation: N. Yen et al., Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53), CANC GENE T, 7(4), 2000, pp. 530-536
Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides
Authors: Anderson, RW Kudelka, AP Honda, T Pollack, MS Gershenson, DM Gillogly, MA Murray, JL Ioannides, CG
Citation: Rw. Anderson et al., Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides, CANCER IMMU, 49(9), 2000, pp. 459-468
Clinical trials of HER-2/neu-specific vaccines
Authors: Murray, JL Przepiorka, D Ioannides, CG
Citation: Jl. Murray et al., Clinical trials of HER-2/neu-specific vaccines, SEMIN ONCOL, 27(6), 2000, pp. 71-75
Oxidant-induced S-gutathiolation inactivates protein kinase C-alpha (PKC-alpha): A potential mechanism of PKC isozyme regulation
Authors: Ward, NE Stewart, JR Ioannides, CG O'Brian, CA
Citation: Ne. Ward et al., Oxidant-induced S-gutathiolation inactivates protein kinase C-alpha (PKC-alpha): A potential mechanism of PKC isozyme regulation, BIOCHEM, 39(33), 2000, pp. 10319-10329
Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers
Authors: Peoples, GE Anderson, BW Lee, TV Murray, JL Kudelka, AP Wharton, JT Ioannides, CG
Citation: Ge. Peoples et al., Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers, CLIN CANC R, 5(12), 1999, pp. 4214-4223
HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells
Authors: Anderson, LD Hudson, JM Savary, CA Fisk, B Gershenson, DM Ioannides, CG
Citation: Ld. Anderson et al., HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells, CANCER IMMU, 48(7), 1999, pp. 401-410
Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients
Authors: Kim, DK Lee, TV Castilleja, A Anderson, BW Peoples, GE Kudelka, AP Murray, JL Sittisomwong, T Wharton, JT Kim, JW Ioannides, CG
Citation: Dk. Kim et al., Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients, ANTICANC R, 19(4B), 1999, pp. 2907-2916
Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism
Authors: Stewart, JR Ward, NE Ioannides, CG O'Brian, CA
Citation: Jr. Stewart et al., Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism, BIOCHEM, 38(40), 1999, pp. 13244-13251
Ovarian cancer-associated lymphocyte recognition of folate binding proteinpeptides
Authors: Peoples, GE Anderson, BW Fisk, B Kudelka, AP Wharton, JT Ioannides, CG
Citation: Ge. Peoples et al., Ovarian cancer-associated lymphocyte recognition of folate binding proteinpeptides, ANN SURG O, 5(8), 1998, pp. 743-750
Ovarian and breast cytotoxic T lymphocytes can recognize peptides from theamino enhancer of split protein of the Notch complex
Authors: Babcock, B Anderson, BW Papayannopoulos, I Castilleja, A Murray, JL Stifani, S Kudelka, AP Wharton, JT Ioannides, CG
Citation: B. Babcock et al., Ovarian and breast cytotoxic T lymphocytes can recognize peptides from theamino enhancer of split protein of the Notch complex, MOL IMMUNOL, 35(17), 1998, pp. 1121-1133
Risultati: 1-15 |